Read in 3 min.
In this article
What was announced in KOEDA’s March 2026 pre-Series A funding round??
On March 31, 2026, KOEDA announced a new capital raise through a third-party allotment. Mitsubishi UFJ Capital (MUCAP) joined as a new investor, alongside a follow-on investment from Tohoku University Venture Partners (THVP) as part of KOEDA's pre-Series A round.
How will the capital support KOEDA's next steps?
The funding is intended to support the following initiatives:
- Driving further commercial development and accelerating marketing and sales activities toward a commercial launch in 2030
- Advancing domestic pivotal clinical trials
- Preparing for regulatory approval and reimbursement in Japan
- Strengthening Quality Management Systems (QMS)
- Preparing for U.S. Food and Drug Administration (FDA) approval
KOEDA Secures Pre-Series A Funding to Advance Pivotal Trials and Commercialization
Funding the Next Stage of Execution
In March 2026, KOEDA secured a pre-Series A capital raise through a third-party allotment. Mitsubishi UFJ Capital (MUCAP) joined as a new investor alongside a JPY 100 million follow-on investment from existing partner Tohoku University Venture Partners (THVP). This funding bridges the gap between early clinical work and the infrastructure required for commercial expansion.
"We would like to extend our sincere appreciation to our investors for their trust and continued support."
— Mike Yagi, Managing Director and COO, KOEDA Inc.
Advancing Toward a Domestic Pivotal Trial
KOEDA is developing the KOEDA™ Endoscopic Anchor System, designed to stabilize target tissues during interventional EUS procedures such as EUS-GBD and EUS-GJ. Following a successful 2025 first-in-human exploratory trial for acute cholecystitis, the company’s immediate objective is a domestic pivotal trial to generate robust, structured evidence for Japanese manufacturing, marketing approval, and national health insurance reimbursement.
Strengthening Quality and Regulatory Readiness
The project has continued to benefit from complementary expertise and practical perspectives throughout its development, combining clinical understanding with engineering know-how to refine both the device and its intended applications.
Global Expansion and the 2030 Launch
Beyond Japan, the financing funds preparations for U.S. FDA approval, global market entry, and commercialization strategies—including supply chain planning and clinician education—toward a planned 2030 launch.
"We have just closed a new round of investment. The focus now is execution."
— Yukio Nakajima, Director & Co-Founder, R&D & Global Business, KOEDA Inc.